

0897301.119
45377.1024680

22. An isolated polypeptide comprising:
a polypeptide having an amino acid sequence which is at least 95% identical to an amino acid sequence of the polypeptide comprising amino acids 1 to 168 of SEQ ID NO:2.

23. The isolated polypeptide according to claim 21, wherein said isolated polypeptide comprises:

a polypeptide having an amino acid sequence encoded by a polynucleotide comprising a coding polynucleotide which is identical to a polynucleotide encoding the polypeptide comprising amino acids 1 to 307 of SEQ ID NO:2.

24. The isolated polypeptide according to claim 21, wherein said isolated polypeptide comprises a polypeptide having an amino acid sequence identical to amino acids 1 to 168 of SEQ ID NO:2.

25. The isolated polypeptide according to claim 22 wherein said polypeptide consists essentially of the amino acid sequence identical to amino acids 1 to 168 of SEQ ID NO:2.

26. The isolated polypeptide according to claim 21 wherein said coding polynucleotide comprises nucleotides 94 to 597 of SEQ ID NO:1.

27. The isolated polypeptide according to claim 23 wherein said coding polynucleotide comprises nucleotides 94 to 597 of SEQ ID NO:1.

28. The isolated polypeptide according to claim 23 wherein said coding polynucleotide comprises nucleotides 1 to 597 of SEQ ID NO:1.

29. An isolated polypeptide comprising:
a polypeptide having an amino acid sequence encoded by a polynucleotide which is at least 95% identical to the polypeptide coding portion of the human cDNA of ATCC Deposit No. 97132.

30. The isolated polypeptide of claim 29, comprising the mature polypeptide encoded by the human cDNA of ATCC Deposit No. 97132.

31. The isolated polypeptide of claim 29, consisting essentially of a polypeptide identical to the mature polypeptide encoded by the human cDNA of ATCC Deposit No. 97132.

32. A polypeptide produced by a method comprising the step of expressing said polypeptide from a recombinant cell containing a polynucleotide which comprises a coding polynucleotide sequence

which is at least 95% identical to a polynucleotide sequence encoding the polypeptide comprising amino acids 1 to 168 of SEQ ID NO:2.

33. A polypeptide according to claim 32, wherein said coding polynucleotide sequence comprises a polynucleotide sequence identical to the polynucleotide sequence encoding amino acids 1 to 168 of SEQ ID NO:2.

34. A polypeptide according to claim 32, wherein said coding polynucleotide sequence consists essentially of a polynucleotide sequence identical to the polynucleotide sequence encoding amino acids 1 to 168 of SEQ ID NO:2.

35. A polypeptide according to claim 32 wherein said coding polynucleotide sequence comprises nucleotides 94 to 597 of SEQ ID NO:1.

36. A polypeptide produced by a method comprising the step of expressing said polypeptide from a recombinant cell containing a polynucleotide which comprises a coding polynucleotide sequence which is at least 95% identical to the polypeptide coding portion of the human cDNA of ATCC Deposit No. 97132, which encodes a mature polypeptide.

37. A polypeptide according to claim 36, comprising the mature polypeptide encoded by the human cDNA of ATCC Deposit No. 97132.

38. A polypeptide according to claim 36, consisting essentially of the mature polypeptide encoded by the human cDNA of ATCC Deposit No. 97132.

39. A compound effective as an agonist for the polypeptide of claim 21.

40. A compound effective as an antagonist for the polypeptide of claim 21.

41. A method for the treatment of a patient having need of EMAP III comprising: administering to the patient a therapeutically effective amount of the polypeptide of claim 21.

42. The method of Claim 41 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide *in vivo*.

43. A method for the treatment of a patient having need of an agonist for a EMAP III polypeptide comprising: administering to the patient a therapeutically effective amount of the compound of claim 39.

44. A method for the treatment of a patient having need to inhibit EMAP III comprising: administering to the patient a therapeutically effective amount of the antagonist of Claim 40.

45. A process for diagnosing a disease or a susceptibility to a disease related to expression of the polypeptide of claim 21 comprising:

determining a mutation in the nucleic acid sequence encoding said polypeptide.

46. A diagnostic process comprising:

analyzing for the presence of the polypeptide of claim 21 in a sample derived from a host.

47. A method for identifying compounds which bind to and

activate or inhibit a receptor for the polypeptide of claim 21 comprising:

contacting a cell expressing on the surface thereof a receptor for the polypeptide, said receptor being associated with a second

component capable of providing a detectable signal in response to the binding of a compound to said receptor, with a compound to be screened under conditions to permit binding to the receptor; and determining whether the compound binds to and activates or inhibits the receptor by detecting the presence or absence of a signal generated from the interaction of the compound with the receptor.

48. A compound effective as an agonist for the polypeptide of claim 29.

49. A compound effective as an antagonist for the polypeptide of claim 29.

50. A method for the treatment of a patient having need of hABH comprising: administering to the patient a therapeutically effective amount of the polypeptide of claim 29.

51. The method of Claim 50 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide *in vivo*.

08972301 "111899"

52. A method for the treatment of a patient having need of an agonist for a EMAP III polypeptide comprising: administering to the patient a therapeutically effective amount of the compound of claim 48.

53. A method for the treatment of a patient having need to inhibit EMAP III comprising: administering to the patient a therapeutically effective amount of the antagonist of Claim 49.

54. A process for diagnosing a disease or a susceptibility to a disease related to expression of the polypeptide of claim 29 comprising:

determining a mutation in the nucleic acid sequence encoding said polypeptide.

55. A diagnostic process comprising:

analyzing for the presence of the polypeptide of claim 29 in a sample derived from a host.

56. A method for identifying compounds which bind to and activate or inhibit a receptor for the polypeptide of claim 29 comprising:

contacting a cell expressing on the surface thereof a receptor for the polypeptide, said receptor being associated with a second